In previous studies of patients with type 2 diabetes, several urinary markers such as urinary kidney injury molecule 1, urinary neutrophil gelatinase-associated lipocalin, urinary liver-type fatty acid-binding protein, and urinary COOH-terminal propeptide of collagen VI, have been investigated for predicting CVE (13, 15, 27). The gene discussed is LCN2; the disease is type 2 diabetes mellitus.